Status
Conditions
Treatments
About
Streptococcus salivarius K12, an oral probiotic strain, has emerged as a promising tool in promoting oral health. Found naturally in the mouth, S. salivarius K12 works by establishing itself in the oral cavity and producing antimicrobial compounds, such as bacteriocins, including salivaricin A2 (SalA2) and the 2,740-Da salivaricin B (SboB) lantibiotics, which inhibit the growth of harmful bacteria including Streptococcus pyogenes. By maintaining a healthy balance of oral microbiota, this probiotic may help prevent common oral health issues such as bad breath, throat infections, and tooth decay. While further research is needed to fully elucidate its mechanisms and efficacy, S. salivarius K12 holds potential as a natural and safe adjunct to oral hygiene practices for promoting overall oral health and hygiene.
Full description
Numerous clinical studies have delved into the therapeutic potential of Streptococcus salivarius K12 across a broad spectrum of health conditions including prevention of recurrent upper respiratory tract infection such as such as sore throat, tonsillitis, and pharyngitis, in both adults and pediatrics. However, despite this extensive exploration, only limited clinical trials have explicitly focused on assessing its safety profile and human tolerance. Therefore, the primary objective of the present clinical trial is to bridge this gap in knowledge by meticulously evaluating the safety and tolerance of Streptococcus salivarius K12 in human subjects. By conducting comprehensive assessments and closely monitoring participants' responses, this trial aims to elucidate crucial insights into the safety profile and human tolerance of this probiotic strain. The findings gleaned from this clinical trial will not only enhance our understanding of Streptococcus salivarius K12's safety but also provide invaluable guidance for its future evidence-based therapeutic applications in oral health management and disease prevention.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
54 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal